New triple therapy shows promise for tough lung cancer
NCT ID NCT06610734
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a low dose of radiation to a combination of chemotherapy and an immunotherapy drug (adebrelimab) helps people with extensive-stage small cell lung cancer live longer. About 202 adults aged 18-75 who have not had prior treatment for this stage will take part. The goal is to see if this approach improves overall survival and delays cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital of Sichuan University
RECRUITINGSichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lung cancer
- New writing therapy aims to ease fear in advanced cancer patients
- New drug combo aims to outperform standard care in aggressive lung cancer
- New cocktail of drugs shows promise for tough lung cancer
- New drug combo aims to keep lung cancer in check after initial treatment
- Engineered immune cells take aim at tough lung cancer